https://t.co/2k4xdmMzOh SGLT2 Inhibitors and Diabetic Ketoacidosis: Data From the FDA Adverse Event Reporting System
https://t.co/lEXW8Pq88e SGLT2 Inhibitors and Diabetic Ketoacidosis: Data From the FDA Adverse Event Reporting System In 37 individuals (1.54%), DKA was fatal.
RT @DiabetologiaJnl: Watch this short video in which Gian Paolo Fadini discusses his previous publication (https://t.co/GI7W6Yd6wo) in Diab…
RT @DiabetologiaJnl: Watch this short video in which Gian Paolo Fadini discusses his previous publication (https://t.co/GI7W6Yd6wo) in Diab…
RT @DiabetologiaJnl: Watch this short video in which Gian Paolo Fadini discusses his previous publication (https://t.co/GI7W6Yd6wo) in Diab…
Watch this short video in which Gian Paolo Fadini discusses his previous publication (https://t.co/GI7W6Yd6wo) in Diabetologia, which used data from the FDA Adverse Event Reporting System to analyse SGLT2 inhibitor-associated diabetic ketoacidosis (DKA) ht
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6X…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6X…
The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6XVv7O https://t.co/oCetbFFuyZ
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System https://t.co/i4L0xWPoBj via @nuzzel
#KEYA_Smart, diabetic ketoacidosis, DKA. https://t.co/dxM3tUMhUp
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @AliceYYCheng: Crucial limitation: "FAERS data prime pharmacovigilance actions but do not inform on the true risk in clinical practice .…
Crucial limitation: "FAERS data prime pharmacovigilance actions but do not inform on the true risk in clinical practice ..." #sglt2i #DKA https://t.co/0vhDrfM2RE
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @docwas: SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA No pattern identified 1.54% mortality https://t.co/LQ62TN85hw
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @Office_j: 【米国有害事象自主報告FAERSデータベース:SGLT2阻害薬服用例におけるケトアシドーシス報告率比は7.9 [95%CI 7.5-8.4]】 Diabetologia https://t.co/AAAwkoJsuh 印刷版出来 https://t…
RT @Office_j: 【米国有害事象自主報告FAERSデータベース:SGLT2阻害薬服用例におけるケトアシドーシス報告率比は7.9 [95%CI 7.5-8.4]】 Diabetologia https://t.co/AAAwkoJsuh 印刷版出来 https://t…
【米国有害事象自主報告FAERSデータベース:SGLT2阻害薬服用例におけるケトアシドーシス報告率比は7.9 [95%CI 7.5-8.4]】 Diabetologia https://t.co/AAAwkoJsuh 印刷版出来 https://t.co/rTbpJyQ7WM
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @docwas: SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA No pattern identified 1.54% mortality https://t.co/LQ62TN85hw
RT @ABCDiab: SGLT2i-associated DKA may not be limited to any particular demographic or comorbid subpopulation. 1.54% Mortality https://t.co…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @ABCDiab: SGLT2i-associated DKA may not be limited to any particular demographic or comorbid subpopulation. 1.54% Mortality https://t.co…
RT @docwas: SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA No pattern identified 1.54% mortality https://t.co/LQ62TN85hw
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA No pattern identified 1.54% mortality https://t.co/LQ62TN85hw
RT @ABCDiab: SGLT2i-associated DKA may not be limited to any particular demographic or comorbid subpopulation. 1.54% Mortality https://t.co…
RT @ABCDiab: SGLT2i-associated DKA may not be limited to any particular demographic or comorbid subpopulation. 1.54% Mortality https://t.co…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @ABCDiab: SGLT2i-associated DKA may not be limited to any particular demographic or comorbid subpopulation. 1.54% Mortality https://t.co…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @ABCDiab: SGLT2i-associated DKA may not be limited to any particular demographic or comorbid subpopulation. 1.54% Mortality https://t.co…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @ABCDiab: SGLT2i-associated DKA may not be limited to any particular demographic or comorbid subpopulation. 1.54% Mortality https://t.co…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @ABCDiab: SGLT2i-associated DKA may not be limited to any particular demographic or comorbid subpopulation. 1.54% Mortality https://t.co…
RT @ABCDiab: SGLT2i-associated DKA may not be limited to any particular demographic or comorbid subpopulation. 1.54% Mortality https://t.co…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
SGLT2i-associated DKA may not be limited to any particular demographic or comorbid subpopulation. 1.54% Mortality https://t.co/cQ9qclluVN
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Yd6wo https://t.co/XTmZKGs4LH
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
RT @DiabetologiaJnl: The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Y…
The largest case-series of SGLT2i-associated DKA comes from the FDA adverse event reporting system https://t.co/GI7W6Yd6wo https://t.co/0KWkM2cGFu
RT @moreno_perez_o: CAD y iSGLT2, registro FDA, datos sesgados. Recordad: Incidencia muy baja en vida real y riesgo / BENEFICIO 👌🏻https://t…
RT @moreno_perez_o: CAD y iSGLT2, registro FDA, datos sesgados. Recordad: Incidencia muy baja en vida real y riesgo / BENEFICIO 👌🏻https://t…
RT @moreno_perez_o: CAD y iSGLT2, registro FDA, datos sesgados. Recordad: Incidencia muy baja en vida real y riesgo / BENEFICIO 👌🏻https://t…
RT @moreno_perez_o: CAD y iSGLT2, registro FDA, datos sesgados. Recordad: Incidencia muy baja en vida real y riesgo / BENEFICIO 👌🏻https://t…
RT @moreno_perez_o: CAD y iSGLT2, registro FDA, datos sesgados. Recordad: Incidencia muy baja en vida real y riesgo / BENEFICIO 👌🏻https://t…
RT @moreno_perez_o: CAD y iSGLT2, registro FDA, datos sesgados. Recordad: Incidencia muy baja en vida real y riesgo / BENEFICIO 👌🏻https://t…
RT @moreno_perez_o: CAD y iSGLT2, registro FDA, datos sesgados. Recordad: Incidencia muy baja en vida real y riesgo / BENEFICIO 👌🏻https://t…
RT @moreno_perez_o: CAD y iSGLT2, registro FDA, datos sesgados. Recordad: Incidencia muy baja en vida real y riesgo / BENEFICIO 👌🏻https://t…
RT @moreno_perez_o: CAD y iSGLT2, registro FDA, datos sesgados. Recordad: Incidencia muy baja en vida real y riesgo / BENEFICIO 👌🏻https://t…
RT @moreno_perez_o: CAD y iSGLT2, registro FDA, datos sesgados. Recordad: Incidencia muy baja en vida real y riesgo / BENEFICIO 👌🏻https://t…
RT @moreno_perez_o: CAD y iSGLT2, registro FDA, datos sesgados. Recordad: Incidencia muy baja en vida real y riesgo / BENEFICIO 👌🏻https://t…
RT @moreno_perez_o: CAD y iSGLT2, registro FDA, datos sesgados. Recordad: Incidencia muy baja en vida real y riesgo / BENEFICIO 👌🏻https://t…
RT @moreno_perez_o: CAD y iSGLT2, registro FDA, datos sesgados. Recordad: Incidencia muy baja en vida real y riesgo / BENEFICIO 👌🏻https://t…
CAD y iSGLT2, registro FDA, datos sesgados. Recordad: Incidencia muy baja en vida real y riesgo / BENEFICIO 👌🏻https://t.co/MsCAhGZIuE https://t.co/NtgipMMYnz
RT @NatureRevEndo: #Diabetic ketoacidosis (#DKA) and #SGLT2 inhibitors: new data from the #FDA Adverse Event Reporting System https://t.co/…
RT @NatureRevEndo: #Diabetic ketoacidosis (#DKA) and #SGLT2 inhibitors: new data from the #FDA Adverse Event Reporting System https://t.co/…
RT @NatureRevEndo: #Diabetic ketoacidosis (#DKA) and #SGLT2 inhibitors: new data from the #FDA Adverse Event Reporting System https://t.co/…
RT @NatureRevEndo: #Diabetic ketoacidosis (#DKA) and #SGLT2 inhibitors: new data from the #FDA Adverse Event Reporting System https://t.co/…
Ensure those on #SGLT2i aware of #dka & consider checking capabilities urine or fingerprick ketones https://t.co/PGBYyJAQLk
SGLT-2i and risk for DKA..more data, more questions... https://t.co/rJmlBWLByC
RT @NatureRevEndo: #Diabetic ketoacidosis (#DKA) and #SGLT2 inhibitors: new data from the #FDA Adverse Event Reporting System https://t.co/…
RT @NatureRevEndo: #Diabetic ketoacidosis (#DKA) and #SGLT2 inhibitors: new data from the #FDA Adverse Event Reporting System https://t.co/…
RT @NatureRevEndo: #Diabetic ketoacidosis (#DKA) and #SGLT2 inhibitors: new data from the #FDA Adverse Event Reporting System https://t.co/…
RT @NatureRevEndo: #Diabetic ketoacidosis (#DKA) and #SGLT2 inhibitors: new data from the #FDA Adverse Event Reporting System https://t.co/…
#Diabetic ketoacidosis (#DKA) and #SGLT2 inhibitors: new data from the #FDA Adverse Event Reporting System https://t.co/9FhgRVlXPz
RT @mbotana: Interesante análisis de las cetoacidosis relacionadas con iSGLT2. https://t.co/bN1s5smKWl